New horizons for promising influences of sulforaphane in the management of metabolic syndrome: a mechanistic review
- 19.12.2024
- Review
- Verfasst von
- Mohammad Masoumvand
- Elmira Ramezani
- Yaser Eshaghi Milasi
- Vafa Baradaran Rahimi
- Vahid Reza Askari
- Erschienen in
- Naunyn-Schmiedeberg's Archives of Pharmacology | Ausgabe 5/2025
Abstract
The disorder known as metabolic syndrome (MetS) represents a substantial threat to society since it is linked to a higher risk of heart disease, diabetes, stroke, and other health issues. Although there is no known cure for metabolic syndrome, lifestyle changes in diet and physical activity can help. Sulforaphane (SFN), a compound in cruciferous vegetables, has been recognized as a promising treatment for addressing metabolic syndrome. The information was compiled after a thorough search of four databases, PubMed, Scopus, Web of Sciences, and Google Scholar. This analysis includes 86 studies that include clinical and nonclinical SFN investigations in diseases connected to metabolic syndrome. Research has shown that sulforaphane is a prospective treatment option for obesity, type 2 diabetes mellitus (T2-DM), and associated metabolic disorders due to its capacity to regulate fatty acid production and glucose management. Many molecular processes have been investigated, including activating nuclear factor erythroid 2-related factor 2(Nrf2), activating nuclear factor erythroid 2(NF-E2), reducing reactive oxygen species, and upregulating insulin receptor substrate 1(IRS-1) and other suggested mechanisms. The current review established many facts in favor of SFN’s prospective benefits in metabolic syndrome. More studies in this field involving human studies are necessary to determine whether SFN may effectively treat metabolic syndrome.
Anzeige
- Titel
- New horizons for promising influences of sulforaphane in the management of metabolic syndrome: a mechanistic review
- Verfasst von
-
Mohammad Masoumvand
Elmira Ramezani
Yaser Eshaghi Milasi
Vafa Baradaran Rahimi
Vahid Reza Askari
- Publikationsdatum
- 19.12.2024
- Verlag
- Springer Berlin Heidelberg
- Erschienen in
-
Naunyn-Schmiedeberg's Archives of Pharmacology / Ausgabe 5/2025
Print ISSN: 0028-1298
Elektronische ISSN: 1432-1912 - DOI
- https://doi.org/10.1007/s00210-024-03706-3
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.